Last reviewed · How we verify
Sodium hyaluronate eye drops
Sodium hyaluronate forms a protective, lubricating film on the ocular surface to retain moisture and reduce friction.
Sodium hyaluronate forms a protective, lubricating film on the ocular surface to retain moisture and reduce friction. Used for Dry eye syndrome / keratoconjunctivitis sicca, Ocular surface irritation and discomfort.
At a glance
| Generic name | Sodium hyaluronate eye drops |
|---|---|
| Also known as | artificial tears |
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Drug class | Artificial tear / ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Sodium hyaluronate is a naturally occurring polysaccharide that acts as a humectant, binding water molecules to the corneal and conjunctival epithelium. This hydrophilic polymer creates a viscous layer that protects the eye surface, reduces evaporation of tears, and alleviates symptoms of dry eye by maintaining corneal hydration and reducing mechanical irritation.
Approved indications
- Dry eye syndrome / keratoconjunctivitis sicca
- Ocular surface irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation or stinging
- Allergic reaction (rare)
Key clinical trials
- Comparison of Ocular Lubricants in People With Symptoms of Dry Eye (PHASE4)
- Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. (PHASE2)
- Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery (PHASE4)
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PHASE4)
- Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED (NA)
- Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease (NA)
- Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease (NA)
- Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: